Neuraxis, Inc. (NRXS)

Neuraxis will go public soon. The estimated IPO date is February 9, 2023.
IPO Price Range
$7.00 - $9.00
Shares Offered
1,875,000
Deal Size
$15.00M
Chart not available yet
Data will show when the stock starts trading on Feb 9, 2023.
Market Cap 40.66M
Revenue (ttm) 2.54M
Net Income (ttm) -5.62M
Shares Out 5.08M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About NRXS

Neuraxis is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. We are dedicated to advancing science with our proprietary PENFS (Percutaneous Electrical Nerve Field Stimulation) technology, which we developed. The IB-Stim is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. IB-Stim already has market clearance from the FDA for functional abdominal pain associated with IBS in children. FDA has classi... [Read more]

Industry Health Care
IPO Date Feb 9, 2023
Employees 16
Stock Exchange NASDAQ
Ticker Symbol NRXS
Full Company Profile

Financial Performance

Financial Statements

News

Neuraxis IPO Registration Document (S-1)

Neuraxis has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC